Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Drug Development
Drug Development · The big question

Create Medicines Bags $122M to Advance In Vivo CAR-T Therapies

Create Medicines fashions $122M fundraise for in vivo CAR-T dreams

Fierce Biotech1 min readAI-assisted summary
Editorial illustration for Create Medicines fashions $122M fundraise for in vivo CAR-T dreams
Editorial illustration

Summary

A biotechnology company named Create Medicines has just secured $122 million in a new round of funding. This substantial financial backing, known as Series B financing, is earmarked to help the company develop a new wave of treatments called in vivo CAR-T therapies.

Traditional CAR-T therapy is a complex process where a patient's immune cells are removed, modified in a laboratory to fight disease, and then infused back into the body. The term in vivo means that Create Medicines aims to do this genetic reprogramming directly inside the patient. The company hopes to use this approach to treat both oncology, meaning cancer, and autoimmune diseases, where the immune system mistakenly attacks the body.

However, it will be a while before these treatments reach the clinic. The company's therapies are currently in the early stages of development. This means that firm data proving these drugs are safe and effective in humans does not exist yet.

Why it matters.

The $122 million investment highlights strong industry excitement around the concept of in vivo cell therapies. Traditional cell treatments are often time-consuming and difficult to produce. Reprogramming immune cells directly inside the body could theoretically bypass these manufacturing hurdles, potentially making cutting-edge treatments more accessible to patients in the future.

Expanding this technology to tackle autoimmune conditions, alongside traditional cancer targets, addresses a massive need in medicine. Still, because Create Medicines is only in the early stages of building its pipeline, the medical community will need to wait for rigorous clinical trial results before knowing if this approach is truly safe and effective.

From the source

The story in numbers.

Series B fundraise
$122M
Therapeutic target areas (autoimmune and cancer)
2
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Drug Development

A $122M boost for a fast, inside-the-body approach to cell therapy

Create Medicines recently secured $122 million to advance a new class of treatments for cancer and autoimmune diseases. They specialize in CAR-T cell therapy, a treatment that engineers the immune system to fight disease. But instead of the traditional method of removing cells from a patient to alter them in a lab, Create Medicines is developing therapies that work entirely inside the body, a process known as "in vivo" treatment. To achieve this, the therapy uses tiny fat bubbles called lipid nanoparticles to deliver messenger RNA, or mRNA, into the patient. Think of mRNA as a set of biological instructions. Once delivered, these instructions directly teach the patient's existing immune cells, including T cells, natural killer cells, and myeloid cells, to reprogram themselves into disease fighters. The startup has already dosed more than 50 patients, giving it the largest clinical dataset in the in vivo field. They recently began an early-stage clinical trial for an experimental therapy designed to attack solid tumors that carry a specific protein called HER2. Alongside this cancer research, the company is testing other treatments that target proteins called CD19 and BCMA to help patients with autoimmune conditions.

BioPharma Dive1 min read
Drug Development

Supreme Court Protects Access to Common Abortion Pill

The United States Supreme Court has decided to preserve access to mifepristone, a medication used in the most common method of abortion. By rejecting recent restrictions proposed by lower courts, the Supreme Court has ensured that patients can still obtain this widely used drug while an ongoing lawsuit continues to make its way through the legal system. Under this current legal order, patients do not need an in-person visit with a doctor to get the medication. Instead, they are permitted to continue receiving mifepristone directly from pharmacies or through the mail. This ruling maintains the existing distribution methods, meaning that access is expected to remain uninterrupted at least into the following year as further legal proceedings unfold.

STAT News1 min read
Drug Development

Living Implants: Engineered Bacteria Trapped in Gel Fight Infections

What if a medical implant could sense an infection and fight it off automatically? Researchers have created exactly that with a new technology called an "implantable living material." To build it, scientists used a specialized, water-based gel known as a polyvinyl alcohol hydrogel. This material acts as a tiny, flexible fortress. It is uniquely stiff and tough, designed to hold genetically engineered bacteria safely inside for up to six months without them escaping into the surrounding tissue. Inside this protective gel, the researchers trapped a modified version of E. coli bacteria to act as molecular guards. These engineered microbes are programmed to detect chemical signals given off by Pseudomonas aeruginosa, a dangerous pathogen that frequently causes infections around artificial joints. When the trapped bacteria sense the invader, they trigger a targeted self-destruct mechanism. This intentional cellular explosion releases a powerful antibacterial protein that easily passes through the microscopic pores of the gel to kill the infection outside. The research team tested this system in mice with artificial joint infections. Over a three-day treatment period, the living implant significantly reduced the amount of infectious bacteria compared to non-therapeutic controls. By keeping the helpful microbes physically contained while allowing their medicine to flow out, the researchers have found a clever way to turn living cells into localized drug factories.

GEN2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗
Create Medicines Bags $122M to Advance In Vivo CAR-T Therapies — Daily Strand